Impact of immigration status on survival among stage 1 and 2 HER2-positive and triple-negative breast cancer in Ontario, Canada
Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E. Cancer Med. 2025; 14(19):e71288.
Publications
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis
Mata DGMM, Sutradhar R, Castelo M, Hahn E, Nguyen L, Rodin D, Fatiregun O, Trebinjac S, Paszat L, Eisen A, Jerzak KJ, Rakovitch E. Breast Cancer Res Treat. 2025 Aug 13 [Epub ahead of print].
Appropriate treatment for stage 1 and 2 Her2-positive and triple-negative breast cancer by immigration status in Ontario, Canada
Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E. Clin Breast Cancer. 2025; S1526-8209(25)00209-5. Epub 2025 Jul 18.
Molecular expression assays improve the prediction of local and invasive local recurrence after breast-conserving surgery for ductal carcinoma in situ
Hahn E, Sutradhar R, Paszat L, Nguyen L, Rodin D, Nofech-Mozes S, Trebinjac S, Jerzak KJ, Fong C, Rakovitch E. J Clin Oncol. 2024; JCO2302276. Epub 2024 Jun 28.
Personalizing the treatment of women with ductal carcinoma in situ (DCIS) using the DCIS score: a qualitative study on score use
O’Brien MA, Paszat L, Makuwaza T, Fong C, Rakovitch E. Curr Oncol. 2024; 31(2):975-86. Epub 2024 Feb 10.
Impact of non-adherence to endocrine therapy on recurrence risk in older women with stage I breast cancer after breast-conserving surgery
Rodin D, Sutradhar R, Jerzak KJ, Hahn E, Nguyen L, Castelo M, Fatiregun O, Fong C, Mata DGMM, Trebinjac S, Paszat L, Rakovitch E. Breast Cancer Res Treat. 2023; 201(1):77-87. Epub 2023 Jun 16.
The association between surgical axillary staging, adjuvant treatment use and survival in older women with early stage breast cancer: a population-based study
Castelo M, Sutradhar R, Faught N, Mata DGMM, Hahn E, Nguyen L, Paszat L, Rodin D, Trebinjac S, Fong C, Rakovitch E. Ann Surg Oncol. 2023; 30(7):3901-12. Epub 2023 Mar 14.
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy
Rodin D, Sutradhar R, Nofech-Mozes S, Gu S, Faught N, Hahn E, Fong C, Trebinjac S, Paszat L, Rakovitch E. Breast Cancer Res Treat. 2022; 192(1):223-33. Epub 2022 Jan 27.
21-gene assay and breast cancer mortality in ductal carcinoma in situ
Rakovitch E, Sutradhar R, Nofech-Mozes S, Gu S, Fong C, Hanna W, Paszat L. J Natl Cancer Inst. 2021; 113(5):572-9. Epub 2020 Dec 28.
The impact of ductal carcinoma in situ on health services utilization
Paszat L, Sutradhar R, Rakovitch E. Breast Cancer Res Treat. 2020; 182(1):159–68. Epub 2020 May 8.